News and Trends 14 Nov 2017 British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that […] November 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 13 Nov 2017 Where is the Money Going in Biotech? A Peek into European VC Strategy Hubert Birner, Managing Partner at TVM Capital Life Science, discusses his strategy to adapt to the European funding constraints and the areas with most potential for biotech investment. TVM Capital Life Science is a venture capital firm focusing on biotech, pharma and medtech. With over €900M under management and offices in both Munich and Montreal, TVM […] November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […] November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 Phase I Results are in for Swedish Biotech’s Cancer Antibody Alligator Bioscience has reported promising results from a Phase I study, where its candidate has been well tolerated in patients with late-stage solid tumors. Alligator Bioscience, located in Lund, Sweden, develops antibody-based immunotherapies to fight cancer. Its pipeline includes clinical and pre-clinical drug candidates, including ADC-1013 and ATOR-1015, as well as novel research candidates. The company […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines NousCom is developing semi-personalized medicine that convinced investors like Abingworth to go in big for its off-the-shelf neoantigen vaccines. Based in Basel and run by a team of serial entrepreneurs with over 15 years of experience, NousCom is finding the middle ground between broadly applicable treatments and personalized medicine. “We are the only company working […] November 6, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 German Pharmacist Finds a Way to Put the Brakes on Gallbladder Cancer Research has identified a protein that drives tumor growth, which opens up a new therapeutic target for gallbladder cancer. Gallbladder cancer is often detected too late to be treated effectively as it shows few symptoms. Research, published in Oncotarget, has identified a pathway that could help to improve prognosis and treatment of the disease. Sonja Kessler discovered […] October 30, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 26 Oct 2017 Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much to show for themselves besides Amgen’s Imlygic, but PsiOxus, one of our top Oxford biotechs, has some ideas to make them bear fruit. The company […] October 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 British Researchers Develop Clever Nanoparticles to Kill Cancer Cells The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […] October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 British Scientists Prove that it Takes Very Few Mutations to Cause Cancer Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […] October 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2017 The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and pharma. In 1998, after 10 years working with big pharma, she founded her first company, Bootcamp, to help young professionals […] October 23, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2017 Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK and AstraZeneca have unveiled research that helps us to better understand a key cancer gene, PTEN – reportedly the second most altered gene in cancers. […] October 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email